BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71. [PMID: 17192118 DOI: 10.2165/00019053-200725010-00006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States. Value in Health 2010;13:77-86. [DOI: 10.1111/j.1524-4733.2009.00586.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
2 Ozyurt A, Narin N, Baykan A, Argun M, Pamukcu O, Zararsiz G, Sunkak S, Uzum K. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study: Palivizumab in Congenital Heart Disease. Pediatr Pulmonol 2015;50:1025-32. [DOI: 10.1002/ppul.23102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ramos GF, Kuiper S, Dompeling E, van Asselt AD, de Grauw WJ, Knottnerus JA, van Schayck OC, Schermer TR, Severens JL. Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children. BMC Med Res Methodol 2011;11:150. [PMID: 22070532 DOI: 10.1186/1471-2288-11-150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-9. [PMID: 21499597 DOI: 10.1155/2011/493056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
5 Tetteh E, Morris S. Systematic review of drug administration costs and implications for biopharmaceutical manufacturing. Appl Health Econ Health Policy 2013;11:445-56. [PMID: 23846573 DOI: 10.1007/s40258-013-0045-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis 2008;27:891-9. [PMID: 18629558 DOI: 10.1007/s10096-008-0520-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
7 Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis 2017;17:687. [PMID: 29041909 DOI: 10.1186/s12879-017-2803-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
8 Hussman JM, Li A, Paes B, Lanctôt KL. A review of cost–effectiveness of palivizumab for respiratory syncytial virus. Expert Review of Pharmacoeconomics & Outcomes Research 2014;12:553-67. [DOI: 10.1586/erp.12.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
9 Prescott WA, Doloresco F, Brown J, Paladino JA. Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review. PharmacoEconomics 2010;28:279-93. [DOI: 10.2165/11531860-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
10 Wong TM, Petrovsky N, Bissel SJ, Wiley CA, Ross TM. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology. Hum Vaccin Immunother 2016;12:2096-105. [PMID: 27215855 DOI: 10.1080/21645515.2016.1162931] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
11 Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14:521-32. [PMID: 20885804 DOI: 10.1093/pch/14.8.521] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
12 Uçkay I, Gasche-Soccal PM, Kaiser L, Stern R, Mazza-Stalder J, Aubert JD, van Delden C. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant 2010;29:299-305. [PMID: 19837611 DOI: 10.1016/j.healun.2009.08.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
13 Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 2008;378:79-85. [PMID: 18556039 DOI: 10.1016/j.virol.2008.04.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
14 Embleton ND, Dharmaraj ST, Deshpande S. Cost-effectiveness of palivizumab in infancy. Expert Rev Pharmacoecon Outcomes Res 2007;7:445-58. [PMID: 20528390 DOI: 10.1586/14737167.7.5.445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
15 Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J. 2012;31:e1-e8. [PMID: 21960187 DOI: 10.1097/inf.0b013e318235455b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
16 Chaw PS, Hua L, Cunningham S, Campbell H, Mikolajczyk R, Nair H; RESCEU Investigators. Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infections in Children With Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis. J Infect Dis 2020;222:S620-7. [PMID: 31825072 DOI: 10.1093/infdis/jiz492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 ter Meulen J. Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opin Emerg Drugs 2007;12:525-40. [PMID: 17979597 DOI: 10.1517/14728214.12.4.525] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
18 Mohapatra SS, Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev 2008;21:495-504. [PMID: 18625684 DOI: 10.1128/CMR.00054-07] [Cited by in Crossref: 82] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
19 Resch B, Resch E, Müller W. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatr Respir Rev 2013;14:130-6. [PMID: 23375547 DOI: 10.1016/j.prrv.2012.12.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
20 Bentley A, Filipovic I, Gooch K, Büsch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev 2013;3:18. [PMID: 23919494 DOI: 10.1186/2191-1991-3-18] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
21 González de Dios J, Ochoa Sangrador C. Conferencia de Consenso sobre bronquiolitis aguda (I): metodología y recomendaciones. Anales de Pediatría 2010;72:221.e1-221.e33. [DOI: 10.1016/j.anpedi.2009.11.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
22 Paes B, Carbonell-estrany X. Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right? Expert Review of Anti-infective Therapy 2019;17:211-22. [DOI: 10.1080/14787210.2019.1581062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009;35:4. [PMID: 19490659 DOI: 10.1186/1824-7288-35-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
24 Thomas G. A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set. Eur J Health Econ 2018;19:177-87. [PMID: 25557555 DOI: 10.1007/s10198-014-0662-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Schmidt R, Majer I, García Román N, Rivas Basterra A, Grubb E, Medrano López C. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Econ Rev 2017;7:47. [PMID: 29260345 DOI: 10.1186/s13561-017-0181-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Figueras Aloy J, López Sastre J, Medrano López C, Bermúdez-cañete Fernández R, Fernández Pineda L, Bonillo Perales A, Pérez-yarza E, Díaz de Heredia C, Sánchez de Toledo J. Consenso multidisciplinar español sobre la profilaxis de la infección respiratoria pediátrica por virus respiratorio sincitial. Anales de Pediatría 2008;69:63-71. [DOI: 10.1157/13124223] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
27 Medrano López C, García-Guereta L, Fernández Pineda L, Malo Concepción P, Maroto Alvaro E, Santos de Soto J, Lirio Casero J, Suárez Cabrera P, Caballero Martínez F. [Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology.]. An Pediatr (Barc) 2010;72:432.e1-13. [PMID: 20493788 DOI: 10.1016/j.anpedi.2010.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
28 Del Vecchio MT. Apnea with RSV infection in three infants receiving palivizumab. Pediatr Int 2013;55:e159-61. [PMID: 24330303 DOI: 10.1111/ped.12200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80. [PMID: 17727335 DOI: 10.1517/14712598.7.9.1471] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
30 Petrou S. Health economic aspects of late preterm and early term birth. Semin Fetal Neonatal Med 2019;24:18-26. [PMID: 30274904 DOI: 10.1016/j.siny.2018.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol 2010;31:90-5. [PMID: 19915892 DOI: 10.1007/s00246-009-9577-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
32 Österreichische Gesellschaft für Kinder- und Jugendheilkunde (ÖGKJ). Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr Kinderheilkd 2008;156:381-3. [DOI: 10.1007/s00112-008-1722-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
33 Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;:CD006602. [PMID: 23633336 DOI: 10.1002/14651858.CD006602.pub4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
34 Bracht M, Basevitz D, Cranis M, Paulley R. Impact of respiratory syncytial virus: the nurse's perspective. Drugs R D 2011;11:215-26. [PMID: 21902285 DOI: 10.2165/11593140-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
35 Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-15. [PMID: 19967425 DOI: 10.1007/s10198-009-0206-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
36 Berger TM, Aebi C, Duppenthaler A, Stocker M; Swiss Pediatric Surveillance Unit. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005). Infection 2009;37:109-16. [PMID: 19412586 DOI: 10.1007/s15010-008-8130-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
37 Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011;30:510-7. [PMID: 21487331 DOI: 10.1097/INF.0b013e3182184ae7] [Cited by in Crossref: 86] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
38 Pouwels KB, Bozdemir SE, Yegenoglu S, Celebi S, McIntosh ED, Unal S, Postma MJ, Hacimustafaoglu M. Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data. PLoS One 2016;11:e0163567. [PMID: 27689356 DOI: 10.1371/journal.pone.0163567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
39 Borochova K, Niespodziana K, Focke-Tejkl M, Hofer G, Keller W, Valenta R. Dissociation of the respiratory syncytial virus F protein-specific human IgG, IgA and IgM response. Sci Rep 2021;11:3551. [PMID: 33574352 DOI: 10.1038/s41598-021-82893-y] [Reference Citation Analysis]
40 La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther 2013;26:666-71. [PMID: 23523663 DOI: 10.1016/j.pupt.2013.03.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
41 Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective. Can J Cardiol 2011;27:523.e11-5. [PMID: 21664100 DOI: 10.1016/j.cjca.2010.12.064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
42 Chaw PS, Wong SWL, Cunningham S, Campbell H, Mikolajczyk R, Nair H; RESCEU Investigators. Acute Lower Respiratory Infections Associated With Respiratory Syncytial Virus in Children With Underlying Congenital Heart Disease: Systematic Review and Meta-analysis. J Infect Dis 2020;222:S613-9. [PMID: 31599958 DOI: 10.1093/infdis/jiz150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Olchanski N, Hansen RN, Pope E, D'Cruz B, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infect Dis 2018;5:ofy031. [PMID: 29516023 DOI: 10.1093/ofid/ofy031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
44 Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab. Paediatric Respiratory Reviews 2009;10:143-7. [DOI: 10.1016/j.prrv.2009.06.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
45 Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Isr J Health Policy Res 2018;7:63. [PMID: 30554570 DOI: 10.1186/s13584-018-0258-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008;8:529-38. [PMID: 20528363 DOI: 10.1586/14737167.8.6.529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
47 Rodríguez SP, Fariña D, Bauer G. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis. Pediatr Infect Dis J 2008;27:660-1. [PMID: 18520447 DOI: 10.1097/INF.0b013e3181691753] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
48 Adlard N, Kinghorn P, Frew E. Is the UK NICE "reference case" influencing the practice of pediatric quality-adjusted life-year measurement within economic evaluations? Value Health 2014;17:454-61. [PMID: 24969007 DOI: 10.1016/j.jval.2014.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
49 Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, Roberts A. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28:702-6. [PMID: 19461555 DOI: 10.1097/INF.0b013e31819df78e] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
50 Andabaka T, Nickerson JW, Rojas-reyes MX, Rueda JD, Vrca VB, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Evid -Based Child Health 2013;8:2243-376. [DOI: 10.1002/ebch.1950] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
51 Nourbakhsh S, Shoukat A, Zhang K, Poliquin G, Halperin D, Sheffield H, Halperin SA, Langley JM, Moghadas SM. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada. EClinicalMedicine 2021;41:101141. [PMID: 34622186 DOI: 10.1016/j.eclinm.2021.101141] [Reference Citation Analysis]
52 Borochova K, Niespodziana K, Stenberg Hammar K, van Hage M, Hedlin G, Söderhäll C, Focke-Tejkl M, Valenta R. Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G. Vaccines (Basel) 2020;8:E337. [PMID: 32630611 DOI: 10.3390/vaccines8020337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Abraha HY, Lanctôt KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med 2015;9:779-99. [PMID: 26457970 DOI: 10.1586/17476348.2015.1098536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
54 Nuijten M, Lenoir-wijnkoop I. Nutrition economics: An innovative approach to informed public health management. European Journal of Pharmacology 2011;668:S133-7. [DOI: 10.1016/j.ejphar.2011.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Neovius K, Buesch K, Sandström K, Neovius M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr 2011;100:1306-14. [PMID: 21477089 DOI: 10.1111/j.1651-2227.2011.02309.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]